Trials / Completed
CompletedNCT02097524
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 105 (actual)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purposes of this study are to describe the pharmacodynamic effects, safety and pharmacokinetics of a single dose of sarilumab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sarilumab | |
| DRUG | Tocilizumab |
Timeline
- Start date
- 2014-03-01
- Primary completion
- 2015-04-01
- Completion
- 2015-04-01
- First posted
- 2014-03-27
- Last updated
- 2015-05-05
Locations
19 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02097524. Inclusion in this directory is not an endorsement.